EP1319067A2 - Varianten des menschlichen koagulationsfaktors vii - Google Patents
Varianten des menschlichen koagulationsfaktors viiInfo
- Publication number
- EP1319067A2 EP1319067A2 EP01967077A EP01967077A EP1319067A2 EP 1319067 A2 EP1319067 A2 EP 1319067A2 EP 01967077 A EP01967077 A EP 01967077A EP 01967077 A EP01967077 A EP 01967077A EP 1319067 A2 EP1319067 A2 EP 1319067A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- amino acid
- seq
- replaced
- variant
- factor vii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
Definitions
- the invention provides a Factor VII polypeptide with the sequence of SEQ ID NO:1 , wherein five amino acids independently selected from the group consisting of the Lys at position 157, the Lys at position 337, the Asp at position 334, the Ser at position 336, the Val at position 158, the Glu at position 296 and the Met at position 298 of SEQ ID NO:1 have been replaced by different amino acids.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10172126A EP2253703A1 (de) | 2000-09-13 | 2001-09-13 | Varianten des menschlichen Gerinnungsfaktors VII |
EP10161855.1A EP2226385B1 (de) | 2000-09-13 | 2001-09-13 | Varianten des menschlichen Koagulationsfaktors VII |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK200001361 | 2000-09-13 | ||
DKPA200001361 | 2000-09-13 | ||
US23645500P | 2000-09-29 | 2000-09-29 | |
PCT/DK2001/000596 WO2002022776A2 (en) | 2000-09-13 | 2001-09-13 | Human coagulation factor vii variants |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1319067A2 true EP1319067A2 (de) | 2003-06-18 |
Family
ID=26068878
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10172126A Withdrawn EP2253703A1 (de) | 2000-09-13 | 2001-09-13 | Varianten des menschlichen Gerinnungsfaktors VII |
EP10161855.1A Expired - Lifetime EP2226385B1 (de) | 2000-09-13 | 2001-09-13 | Varianten des menschlichen Koagulationsfaktors VII |
EP01967077A Withdrawn EP1319067A2 (de) | 2000-09-13 | 2001-09-13 | Varianten des menschlichen koagulationsfaktors vii |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10172126A Withdrawn EP2253703A1 (de) | 2000-09-13 | 2001-09-13 | Varianten des menschlichen Gerinnungsfaktors VII |
EP10161855.1A Expired - Lifetime EP2226385B1 (de) | 2000-09-13 | 2001-09-13 | Varianten des menschlichen Koagulationsfaktors VII |
Country Status (7)
Country | Link |
---|---|
EP (3) | EP2253703A1 (de) |
JP (2) | JP4361728B2 (de) |
AU (2) | AU2001287550B2 (de) |
HU (1) | HUP0301246A3 (de) |
IL (4) | IL154520A0 (de) |
PL (1) | PL204888B1 (de) |
WO (1) | WO2002022776A2 (de) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
EP2319541A1 (de) | 2000-02-11 | 2011-05-11 | Bayer HealthCare LLC | Faktor VII- oder VIIA-ähnliche Konjugate |
US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6905683B2 (en) | 2000-05-03 | 2005-06-14 | Novo Nordisk Healthcare A/G | Human coagulation factor VII variants |
US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
RU2326126C2 (ru) | 2000-09-13 | 2008-06-10 | Ново Нордиск Хелт Кэр Аг | Полипептид фактора vii свертывания крови, его получение и применение |
WO2002038162A1 (en) | 2000-11-09 | 2002-05-16 | The Scripps Research Institute | MODIFIED FACTOR VIIa |
ES2432967T3 (es) * | 2001-03-22 | 2013-12-05 | Novo Nordisk Health Care Ag | Derivados del Factor VII de coagulación |
KR20040015821A (ko) * | 2001-07-20 | 2004-02-19 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ⅶ 폴리펩티드와 인자 ⅹⅰ폴리펩티드를 포함하는약학적 조성물 |
US7052868B2 (en) | 2001-09-27 | 2006-05-30 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
ES2490590T3 (es) * | 2001-11-02 | 2014-09-04 | Novo Nordisk Health Care Ag | Polipéptidos de factor VII de coagulación humana |
US6960657B2 (en) | 2001-11-02 | 2005-11-01 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
US7125846B2 (en) | 2001-11-09 | 2006-10-24 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides |
AU2002351756A1 (en) | 2001-12-21 | 2003-07-15 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
AU2003221469A1 (en) | 2002-04-30 | 2003-11-17 | Bayer Healthcare Llc | FACTOR VII OR VIIa POLYPEPTIDE VARIANTS |
CA2490342C (en) | 2002-06-21 | 2015-06-16 | Novo Nordisk A/S | Stabilised solid compositions of factor vii polypeptides |
UA86744C2 (en) | 2002-06-21 | 2009-05-25 | Ново Нордиск Хэлс Кеа Аг | Pegylated factor vii glycoforms |
AU2003266214A1 (en) | 2002-09-25 | 2004-04-19 | Novo Nordisk A/S | Human coagulation factor vii polypeptides |
US6911323B2 (en) | 2002-09-25 | 2005-06-28 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
RU2364626C2 (ru) * | 2003-03-18 | 2009-08-20 | Ново Нордиск Хелт Кэр Аг | Способ получения, способ очистки и способ стабилизации полипептидов фактора vii, ix и x |
EP2085470B1 (de) * | 2003-03-20 | 2012-05-16 | Bayer HealthCare LLC | FVII oder FVIIa Varianten |
US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
CN1771080B (zh) | 2003-04-08 | 2010-12-15 | 诺沃挪第克公司 | 包括至少一个色谱处理步骤的生产治疗用多肽或其前体的方法 |
AU2004247799B2 (en) | 2003-06-19 | 2009-12-03 | Bayer Healthcare Llc | Factor VII or VIIa Gla domain variants |
EP1641487B1 (de) | 2003-06-25 | 2012-02-29 | Novo Nordisk Health Care AG | Flüssige zusammensetzungen von factor vii polypeptiden |
ATE547519T1 (de) | 2003-09-09 | 2012-03-15 | Novo Nordisk Healthcare Ag | Gerinnungsfaktor-vii-polypeptide |
EP1673453A2 (de) | 2003-10-07 | 2006-06-28 | Novo Nordisk Health Care AG | Hybridmoleküle mit faktor vii/viia-aktivität |
PL1711513T3 (pl) | 2003-12-01 | 2014-12-31 | Novo Nordisk Healthcare Ag | Nanofiltracja roztworów czynnika vii w celu usunięcia wirusów |
DK2298287T3 (en) | 2003-12-19 | 2018-07-23 | Novo Nordisk Healthcare Ag | Stabilized compositions of factor VII polypeptides |
DK2842576T3 (en) | 2004-01-21 | 2017-10-16 | Novo Nordisk Healthcare Ag | Transglutaminase-mediated peptide conjugation |
JP2007522805A (ja) * | 2004-02-03 | 2007-08-16 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 新規化合物 |
US9187549B2 (en) | 2004-12-23 | 2015-11-17 | Novo Nordisk Healthcare A/G | Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest |
WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
ES2397851T3 (es) | 2005-07-13 | 2013-03-11 | Novo Nordisk Health Care Ag | Células de inactivación proteínica de la célula huésped para la producción de proteínas terapéuticas |
CN101268185B (zh) | 2005-09-01 | 2013-03-27 | 诺沃-诺迪斯克保健股份有限公司 | 因子ⅶ多肽的疏水作用色谱纯化 |
EP1926817A2 (de) * | 2005-09-14 | 2008-06-04 | Novo Nordisk Health Care AG | Menschliche gerinnungsfaktor-vii-polypeptide |
JP5570809B2 (ja) | 2006-09-01 | 2014-08-13 | ノボ ノルディスク ヘルス ケア アーゲー | 修飾タンパク質 |
BRPI0720282B8 (pt) | 2006-12-15 | 2021-05-25 | Baxalta GmbH | construção proteica, composição farmacêutica, e, kit |
WO2008127702A2 (en) | 2007-04-13 | 2008-10-23 | Catalyst Biosciences, Inc. | Modified factor vii polypetides and uses thereof |
SG10201503304RA (en) | 2007-12-27 | 2015-06-29 | Baxter Int | Cell culture processes |
TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子vii多肽和其用途 |
MX2010011721A (es) * | 2008-04-30 | 2010-11-30 | Danisco Inc | Nuevas variantes de alfa-amilasa quimericas. |
EP2285829B1 (de) * | 2008-05-30 | 2015-07-08 | Novo Nordisk Health Care AG | Verfahren zur steuerung einer polypeptidmodifikationsreaktion |
NO2440239T3 (de) | 2009-06-09 | 2018-02-10 | ||
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
CA2769326A1 (en) | 2009-07-27 | 2011-02-10 | Baxter International Inc. | Blood coagulation protein conjugates |
PL2459224T3 (pl) | 2009-07-27 | 2017-08-31 | Baxalta GmbH | Koniugaty białka związanego z krzepnięciem krwi |
RU2533619C2 (ru) | 2009-07-27 | 2014-11-20 | Лайпоксен Текнолоджиз Лимитед | Гликополисиалирование белков, не являющихся белками свертывания крови |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
EP2561070B1 (de) | 2010-04-20 | 2015-06-03 | Octapharma AG | Neuer Stabilisator für pharmazeutische Proteine |
TW201212938A (en) | 2010-06-30 | 2012-04-01 | Novo Nordisk As | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
CA2822591C (en) | 2010-12-22 | 2020-12-29 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
EP2680875B1 (de) | 2011-03-02 | 2019-10-23 | Novo Nordisk Health Care AG | Gerinnungsfaktor-targeting auf tlt-1 auf aktivierten plättchen |
AU2012267484B2 (en) | 2011-06-10 | 2017-03-23 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
EP2554161A1 (de) | 2011-08-02 | 2013-02-06 | LFB Biotechnologies | Pharmazeutische Zusammensetzung enthaltend Faktor VII in Mizellen verkapselt |
WO2014057068A1 (en) | 2012-10-10 | 2014-04-17 | Novo Nordisk Health Care Ag | Liquid pharmaceutical composition of factor vii polypeptide |
JP2015533152A (ja) | 2012-10-15 | 2015-11-19 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 第vii因子コンジュゲート |
AU2014336252A1 (en) | 2013-10-15 | 2016-04-07 | Novo Nordisk Health Care Ag | Coagulation factor VII polypeptides |
MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
DK3402537T3 (da) | 2016-01-15 | 2021-03-29 | Rigshospitalet | Kvantitativ PET-afbildning af vævsfaktorekspression under anvendelse af 18-F mærket, aktiv positions-inhiberet faktor VII |
EP3833381B1 (de) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modifizierte faktor-vii-polypeptide zur subkutanen verabreichung |
CN113336841B (zh) * | 2021-06-02 | 2022-09-23 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | F8蛋白变体及利用其制备的基因治疗载体 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4456591A (en) | 1981-06-25 | 1984-06-26 | Baxter Travenol Laboratories, Inc. | Therapeutic method for activating factor VII |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
GB8615942D0 (en) | 1986-06-30 | 1986-08-06 | Animal & Food Research Council | Peptide production |
NZ221259A (en) | 1986-07-31 | 1990-05-28 | Calgene Inc | Seed specific transcriptional regulation |
DK323587D0 (da) * | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP0279582A3 (de) | 1987-02-17 | 1989-10-18 | Pharming B.V. | DNA-Sequenzen die Proteine zwecks effizienter Abscheidung zur Milchdrüse leiten |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
GB8826446D0 (en) | 1988-11-11 | 1988-12-14 | Agricultural & Food Res | Peptide production |
US5073964A (en) | 1989-08-04 | 1991-12-17 | Aware, Inc. | Signal processing device and method |
US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
EP0521873B1 (de) | 1990-01-29 | 1999-06-02 | Zymogenetics, Inc. | Antikoagulierende proteine |
DE69232310T2 (de) | 1991-01-11 | 2002-08-14 | American Red Cross Washington | Expression von aktivem menschlichem Protein C im Milchdrüsengewebe transgener Tiere |
DE69429429T2 (de) * | 1993-05-21 | 2002-05-16 | Novo Nordisk As | MODIFIZIERTER FAKTOR VII zur Hemmung der vaskulären Restenosis und Thrombozytenablagerung |
EP2319541A1 (de) * | 2000-02-11 | 2011-05-11 | Bayer HealthCare LLC | Faktor VII- oder VIIA-ähnliche Konjugate |
EP1280548B1 (de) * | 2000-05-03 | 2013-12-11 | Novo Nordisk Health Care AG | Subkutane Verabreichung des Koagulationsfaktor VII |
JP4455802B2 (ja) * | 2000-05-03 | 2010-04-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト第vii凝固因子変異型 |
BR0110659A (pt) * | 2000-05-10 | 2003-02-11 | Novo Nordisk As | Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo |
-
2001
- 2001-09-13 EP EP10172126A patent/EP2253703A1/de not_active Withdrawn
- 2001-09-13 IL IL15452001A patent/IL154520A0/xx unknown
- 2001-09-13 EP EP10161855.1A patent/EP2226385B1/de not_active Expired - Lifetime
- 2001-09-13 EP EP01967077A patent/EP1319067A2/de not_active Withdrawn
- 2001-09-13 HU HU0301246A patent/HUP0301246A3/hu unknown
- 2001-09-13 WO PCT/DK2001/000596 patent/WO2002022776A2/en active IP Right Grant
- 2001-09-13 AU AU2001287550A patent/AU2001287550B2/en not_active Ceased
- 2001-09-13 JP JP2002527015A patent/JP4361728B2/ja not_active Expired - Fee Related
- 2001-09-13 PL PL360384A patent/PL204888B1/pl not_active IP Right Cessation
- 2001-09-13 AU AU8755001A patent/AU8755001A/xx active Pending
-
2003
- 2003-02-18 IL IL154520A patent/IL154520A/en not_active IP Right Cessation
-
2009
- 2009-01-13 IL IL196482A patent/IL196482A/en not_active IP Right Cessation
- 2009-06-23 JP JP2009148765A patent/JP4814359B2/ja not_active Expired - Fee Related
-
2010
- 2010-06-07 IL IL206229A patent/IL206229A/en not_active IP Right Cessation
Non-Patent Citations (3)
Title |
---|
PERSSON E ET AL: "RATIONAL DESIGN OF COAGULATION FACTOR VLLA VARIANTS WITH SUBSTANTIALLY INCREASED INTRINSIC ACTIVITY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, WASHINGTON, DC; US, vol. 98, no. 24, 20 November 2001 (2001-11-20), pages 13583 - 13588, XP002909203, ISSN: 0027-8424, DOI: 10.1073/PNAS.241339498 * |
PERSSON EGON ET AL: "Assignment of molecular properties of a superactive coagulation factor VIIa variant to individual amino acid changes", EUROPEAN JOURNAL OF BIOCHEMISTRY, BLACKWELL PUBLISHING, BERLIN, DE, vol. 269, no. 23, 1 December 2002 (2002-12-01), pages 5950 - 5955, XP002309086, ISSN: 0014-2956, DOI: 10.1046/J.1432-1033.2002.03323.X * |
See also references of WO0222776A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002022776A2 (en) | 2002-03-21 |
EP2226385A1 (de) | 2010-09-08 |
PL204888B1 (pl) | 2010-02-26 |
JP4361728B2 (ja) | 2009-11-11 |
HUP0301246A2 (hu) | 2003-08-28 |
JP2009278980A (ja) | 2009-12-03 |
IL196482A (en) | 2011-03-31 |
IL206229A (en) | 2012-02-29 |
IL154520A0 (en) | 2003-09-17 |
WO2002022776A3 (en) | 2002-07-18 |
PL360384A1 (en) | 2004-09-06 |
JP4814359B2 (ja) | 2011-11-16 |
JP2004508822A (ja) | 2004-03-25 |
IL154520A (en) | 2010-06-16 |
AU2001287550B2 (en) | 2007-03-22 |
AU8755001A (en) | 2002-03-26 |
WO2002022776A9 (en) | 2003-05-22 |
HUP0301246A3 (en) | 2005-12-28 |
EP2253703A1 (de) | 2010-11-24 |
EP2226385B1 (de) | 2013-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2226385B1 (de) | Varianten des menschlichen Koagulationsfaktors VII | |
US7695935B2 (en) | Nucleic acids encoding human coagulation FVII polypeptides | |
US7416860B2 (en) | Nucleic acids encoding human coagulation factor VII variants | |
EP1282693B1 (de) | Varianten des menschlichen Koagulationsfaktors VII | |
US7416861B2 (en) | Human coagulation factor VII polypeptides | |
EP1432794B1 (de) | Menschliche gerinnungsfaktor-vii-polypeptide | |
AU2001287550A1 (en) | Human coagulation factor VII variants | |
JP4597678B2 (ja) | ヒト凝固因子viiポリペプチド | |
AU2008261165A1 (en) | Human coagulation factor VII variants | |
AU2002333211A1 (en) | Human coagulation factor VII polypeptides | |
US20080010693A1 (en) | Human coagulation factor VII polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030414 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: OLSEN, OLE, HVILSTED Inventor name: PERSSON, EGON |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NOVO NORDISK HEALTH CARE AG |
|
17Q | First examination report despatched |
Effective date: 20061107 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: OLSEN, OLE, HVILSTED Inventor name: PERSSON, EGON |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NOVO NORDISK HEALTH CARE AG |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20130416 |